Curi RMB Capital LLC Acquires 7,597 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Curi RMB Capital LLC boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 19.4% during the third quarter, HoldingsChannel reports. The fund owned 46,715 shares of the company’s stock after purchasing an additional 7,597 shares during the quarter. Curi RMB Capital LLC’s holdings in CRISPR Therapeutics were worth $2,195,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Capital International Investors boosted its stake in shares of CRISPR Therapeutics by 27.8% in the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock valued at $534,175,000 after purchasing an additional 1,702,624 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after purchasing an additional 46,148 shares during the last quarter. SR One Capital Management LP bought a new stake in shares of CRISPR Therapeutics in the 1st quarter valued at $71,496,000. Dimensional Fund Advisors LP boosted its stake in shares of CRISPR Therapeutics by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after purchasing an additional 19,094 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at $28,625,000. 69.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CRSP shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, November 7th. Rodman & Renshaw began coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. Stifel Nicolaus cut their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Stock Up 0.9 %

CRSP opened at $47.25 on Friday. The company has a market capitalization of $4.03 billion, a price-to-earnings ratio of -16.70 and a beta of 1.67. The firm has a 50-day moving average price of $47.88 and a 200-day moving average price of $52.04. CRISPR Therapeutics AG has a twelve month low of $43.42 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter last year, the company earned ($1.41) earnings per share. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.2 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the transaction, the chief executive officer now owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,382 shares of company stock worth $1,917,679 over the last quarter. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.